1. Home
  2. RPID vs LONA Comparison

RPID vs LONA Comparison

Compare RPID & LONA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rapid Micro Biosystems Inc.

RPID

Rapid Micro Biosystems Inc.

SELL

Current Price

$0.74

Market Cap

34.7M

Sector

Health Care

ML Signal

SELL

Logo LeonaBio Inc. Common Stock

LONA

LeonaBio Inc. Common Stock

HOLD

Current Price

$3.26

Market Cap

32.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RPID
LONA
Founded
2006
2011
Country
United States
United States
Employees
N/A
19
Industry
Medical Specialities
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
34.7M
32.7M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
RPID
LONA
Price
$0.74
$3.26
Analyst Decision
Strong Buy
Buy
Analyst Count
4
4
Target Price
$6.00
★ $16.67
AVG Volume (30 Days)
★ 151.4K
56.3K
Earning Date
11-27-2026
11-27-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 2.78
N/A
EPS
★ N/A
N/A
Revenue
★ $33,587,000.00
N/A
Revenue This Year
$16.95
N/A
Revenue Next Year
$17.92
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 19.74
N/A
52 Week Low
$0.58
$2.21
52 Week High
$4.94
$14.21

Technical Indicators

Market Signals
Indicator
RPID
LONA
Relative Strength Index (RSI) 44.29 26.74
Support Level $0.58 $2.21
Resistance Level $2.18 $9.78
Average True Range (ATR) 0.07 0.44
MACD 0.01 -0.10
Stochastic Oscillator 66.24 3.27

Price Performance

Historical Comparison
RPID
LONA

About RPID Rapid Micro Biosystems Inc.

Rapid Micro Biosystems Inc is a life sciences technology company. Its technology uses a sensitive camera and the natural autofluorescence of living cells to identify and quantify microbial growth faster and more accurately than the traditional method, which relies on the human eye. The company develops, manufactures, markets, and sells Growth Direct systems (Systems), proprietary consumables, laboratory information management system (LIMS) connection, and other software and services to address rapid microbial analysis used for quality control in the manufacture of pharmaceuticals, medical devices, and personal care products. Geographically, it generates maximum revenue from the United States, and the rest from Switzerland, Germany, Japan, and all other countries.

About LONA LeonaBio Inc. Common Stock

LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a single operating segment, developing and commercializing therapeutics.

Share on Social Networks: